The rebinyn or refixia market research report is one of a series of new reports that provides rebinyn or refixia market statistics, including rebinyn or refixia industry global market size, regional shares, competitors with rebinyn or refixia market share, detailed rebinyn or refixia market segments, market trends and opportunities, and any further data you may need to thrive in the rebinyn or refixia industry. This rebinyn or refixia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to market demand for hemophilia treatments, regulatory support, partnerships with healthcare providers, global market expansion, and increasing prevalence of hemophilia. Major trends in the forecast period include advancements in hemophilia research, international guidelines development, digital health integration, patient-centric research approaches, and technological innovations in drug development.
The increasing prevalence of hemophilia is expected to drive the growth of the rebinyn or refixia market. Hemophilia is an inherited bleeding disorder where the blood doesn't clot properly, causing excessive bleeding from injuries or spontaneously, often requiring medical intervention. The rise in hemophilia cases can be attributed to genetic factors, greater awareness of acquired forms, and improvements in diagnostic practices, which have led to better identification of previously undiagnosed individuals. Rebinyn or Refixia is used to manage hemophilia B by providing long-lasting protection against bleeding episodes through factor IX replacement therapy. For example, according to the United Kingdom Hemophilia Centre Doctors’ Organization, the number of new registrations for Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. Thus, the rising incidence of hemophilia is a key driver of the Rebinyn or Refixia market.
An increase in healthcare expenditure is also expected to support the growth of the rebinyn or refixia market. Healthcare expenditure refers to the total amount spent on health services and related activities over a specific period. This expenditure is rising due to factors such as an aging population, the prevalence of chronic diseases, higher service prices, technological advancements, rising drug costs, medical inflation, and the ongoing effects of the COVID-19 pandemic. Higher healthcare spending improves accessibility and affordability for treatments such as Rebinyn or Refixia, making it easier for individuals to manage hemophilia B effectively. For instance, a report from the Office for National Statistics in May 2024 indicated that healthcare expenditure in the UK rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Additionally, long-term health and social care spending increased by 2.8% in real terms in 2022. As a result, growing healthcare expenditure is playing a significant role in driving the Rebinyn or Refixia market.
A key development in the rebinyn or refixia market is the FDA approval of Rebinyn for routine prophylaxis in individuals with hemophilia B. This approval provides a more effective treatment option for managing hemophilia B and helps reduce the risk of bleeding episodes. For instance, in July 2022, Novo Nordisk received FDA approval for REBINYN (coagulation factor IX [recombinant], GlycoPEGylated) for routine prophylaxis in hemophilia B patients. This approval expanded its use to both adults and children to prevent bleeding episodes, marking a significant advancement in the treatment of this genetic disorder.
The key company operating in the rebinyn or refixia market is Novo Nordisk A/S.
North America was the largest region in the rebinyn or refixia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rebinyn or refixia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rebinyn or refixia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rebinyn, also known as Refizia in certain regions, is a long-acting recombinant factor IX (FIX) therapy designed to treat and prevent bleeding episodes in individuals with hemophilia B. Engineered with extended half-life properties, it reduces the frequency of injections needed for effective management. Rebinyn works by replacing the deficient FIX protein in patients with hemophilia B, promoting proper blood clotting. It is used for routine prophylaxis, on-demand treatment, and to manage bleeding during surgeries. The extended half-life enhances patient convenience and improves their overall quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary formulations of rebinyn or refizia are intravenous injections and lyophilized powders. Intravenous injections deliver the medication directly into a vein for quick absorption into the bloodstream. These formulations are primarily used for managing hemophilia B, preventing bleeding episodes, and controlling bleeding on demand across various patient groups, including pediatric, adult, and geriatric populations. The main users include hospitals, clinics, and home care settings, with distribution channels that include hospital pharmacies, retail pharmacies, and online pharmacies.
The rebinyn or refixia market consists of sales of recombinant factor IX (FIX) products and blood clotting replacement solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to market demand for hemophilia treatments, regulatory support, partnerships with healthcare providers, global market expansion, and increasing prevalence of hemophilia. Major trends in the forecast period include advancements in hemophilia research, international guidelines development, digital health integration, patient-centric research approaches, and technological innovations in drug development.
The increasing prevalence of hemophilia is expected to drive the growth of the rebinyn or refixia market. Hemophilia is an inherited bleeding disorder where the blood doesn't clot properly, causing excessive bleeding from injuries or spontaneously, often requiring medical intervention. The rise in hemophilia cases can be attributed to genetic factors, greater awareness of acquired forms, and improvements in diagnostic practices, which have led to better identification of previously undiagnosed individuals. Rebinyn or Refixia is used to manage hemophilia B by providing long-lasting protection against bleeding episodes through factor IX replacement therapy. For example, according to the United Kingdom Hemophilia Centre Doctors’ Organization, the number of new registrations for Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. Thus, the rising incidence of hemophilia is a key driver of the Rebinyn or Refixia market.
An increase in healthcare expenditure is also expected to support the growth of the rebinyn or refixia market. Healthcare expenditure refers to the total amount spent on health services and related activities over a specific period. This expenditure is rising due to factors such as an aging population, the prevalence of chronic diseases, higher service prices, technological advancements, rising drug costs, medical inflation, and the ongoing effects of the COVID-19 pandemic. Higher healthcare spending improves accessibility and affordability for treatments such as Rebinyn or Refixia, making it easier for individuals to manage hemophilia B effectively. For instance, a report from the Office for National Statistics in May 2024 indicated that healthcare expenditure in the UK rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Additionally, long-term health and social care spending increased by 2.8% in real terms in 2022. As a result, growing healthcare expenditure is playing a significant role in driving the Rebinyn or Refixia market.
A key development in the rebinyn or refixia market is the FDA approval of Rebinyn for routine prophylaxis in individuals with hemophilia B. This approval provides a more effective treatment option for managing hemophilia B and helps reduce the risk of bleeding episodes. For instance, in July 2022, Novo Nordisk received FDA approval for REBINYN (coagulation factor IX [recombinant], GlycoPEGylated) for routine prophylaxis in hemophilia B patients. This approval expanded its use to both adults and children to prevent bleeding episodes, marking a significant advancement in the treatment of this genetic disorder.
The key company operating in the rebinyn or refixia market is Novo Nordisk A/S.
North America was the largest region in the rebinyn or refixia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rebinyn or refixia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rebinyn or refixia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rebinyn, also known as Refizia in certain regions, is a long-acting recombinant factor IX (FIX) therapy designed to treat and prevent bleeding episodes in individuals with hemophilia B. Engineered with extended half-life properties, it reduces the frequency of injections needed for effective management. Rebinyn works by replacing the deficient FIX protein in patients with hemophilia B, promoting proper blood clotting. It is used for routine prophylaxis, on-demand treatment, and to manage bleeding during surgeries. The extended half-life enhances patient convenience and improves their overall quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary formulations of rebinyn or refizia are intravenous injections and lyophilized powders. Intravenous injections deliver the medication directly into a vein for quick absorption into the bloodstream. These formulations are primarily used for managing hemophilia B, preventing bleeding episodes, and controlling bleeding on demand across various patient groups, including pediatric, adult, and geriatric populations. The main users include hospitals, clinics, and home care settings, with distribution channels that include hospital pharmacies, retail pharmacies, and online pharmacies.
The rebinyn or refixia market consists of sales of recombinant factor IX (FIX) products and blood clotting replacement solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rebinyn Or Refixia Market Characteristics4. Rebinyn Or Refixia Market Trends And Strategies5. Rebinyn Or Refixia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Rebinyn Or Refixia Pricing Analysis & Forecasts30. Global Rebinyn Or Refixia Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Rebinyn Or Refixia Market32. Recent Developments In The Rebinyn Or Refixia Market
3. Rebinyn Or Refixia Market Biologic Drug Characteristics
6. Global Rebinyn Or Refixia Growth Analysis And Strategic Analysis Framework
8. Rebinyn Or Refixia Market Segmentation
9. Global Rebinyn Or Refixia Epidemiology Of Clinical Indications
10. Rebinyn Or Refixia Market Regional And Country Analysis
11. Asia-Pacific Rebinyn Or Refixia Market
12. China Rebinyn Or Refixia Market
13. India Rebinyn Or Refixia Market
14. Japan Rebinyn Or Refixia Market
15. Australia Rebinyn Or Refixia Market
16. South Korea Rebinyn Or Refixia Market
17. Western Europe Rebinyn Or Refixia Market
18. UK Rebinyn Or Refixia Market
19. Germany Rebinyn Or Refixia Market
20. France Rebinyn Or Refixia Market
21. Eastern Europe Rebinyn Or Refixia Market
22. North America Rebinyn Or Refixia Market
23. USA Rebinyn Or Refixia Market
24. Canada Rebinyn Or Refixia Market
25. South America Rebinyn Or Refixia Market
26. Middle East Rebinyn Or Refixia Market
27. Africa Rebinyn Or Refixia Market
28. Rebinyn Or Refixia Market Competitive Landscape And Company Profiles
29. Global Rebinyn Or Refixia Market Pipeline Analysis
33. Rebinyn Or Refixia Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Rebinyn Or Refixia Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rebinyn or refixia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rebinyn or refixia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rebinyn or refixia market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Intravenous Injection; Lyophilized Powder2) By Indication: Hemophilia B Management; Prevention Of Bleeding Episodes; On-Demand Bleeding Control
3) By Patient Demographics: Pediatric Patients; Adults; Geriatric Patients
4) By End Users: Hospitals; Clinics; Homecare Settings
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Key Companies Profiled: Novo Nordisk A/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novo Nordisk A/S